文献速递妇产影像US

孕中期解剖超声诊断的巨大儿与妊娠期糖尿病及出生时巨大儿的关联

Large-for-gestational age diagnosed during second-trimester anatomy ultrasound and association with gestational diabetes and large-for-gestational age at birth.
PubMed 文献 · Ultrasound Obstet Gynecol · 2020-01-01

该回顾性队列研究纳入2012至2017年在本机构于孕18至22周接受孕中期解剖超声检查的孕妇,比较孕中期超声诊断的巨大儿(756例)与适龄儿(756例)。调整年龄、产次、孕期体重指数变化、肥胖、种族及新生儿性别后,孕中期巨大儿与妊娠期糖尿病(aOR 2.54;95%CI 1.29-5.03;P=0.007)及出生时巨大儿(aOR 6.85;95%CI 3.60-13.05;P<0.0001)显著相关。作者认为孕中期超声诊断的巨大儿可用于早期识别这些孕妇以进行干预。

要点

  • 孕中期解剖超声发现估计胎儿体重和/或腹围≥90百分位时,需警惕后续妊娠期糖尿病及出生时巨大儿风险。
  • 孕中期巨大儿组妊娠期糖尿病发生率为6.0%,出生时巨大儿发生率为14.9%。
  • 调整混杂因素后,孕中期巨大儿与妊娠期糖尿病的aOR为2.54(95%CI 1.29-5.03;P=0.007),与出生时巨大儿的aOR为6.85(95%CI 3.60-13.05;P<0.0001)。

核心结论

  • 孕中期超声诊断的巨大儿与妊娠期糖尿病及出生时巨大儿独立相关,可用于早期识别这些孕妇以进行干预。

研究设计与样本

  • 回顾性队列研究,纳入2012至2017年在本机构于孕18至22周接受孕中期解剖超声检查的孕妇。
  • 巨大儿组756例(估计胎儿体重和/或胎儿腹围≥90百分位),对照组为适龄儿756例(估计胎儿体重>10百分位且≤89百分位)。
  • 排除既往孕前糖尿病、多胎妊娠、早产、使用倍他米松或胎儿畸形者;回顾产前及分娩记录,采用多变量logistic回归分析。

诊断标准与关键数值

  • 巨大儿诊断标准:估计胎儿体重和/或胎儿腹围≥90百分位(孕中期超声)。
  • 适龄儿定义:估计胎儿体重>10百分位且≤89百分位。
  • 出生时巨大儿定义:出生体重≥90百分位。
  • 孕中期巨大儿组妊娠期糖尿病发生率6.0%,出生时巨大儿发生率14.9%。
  • 调整年龄、产次、孕期体重指数变化、肥胖、种族及新生儿性别后,孕中期巨大儿与妊娠期糖尿病aOR 2.54(95%CI 1.29-5.03;P=0.007),与出生时巨大儿aOR 6.85(95%CI 3.60-13.05;P<0.0001)。

临床应用与阅片要点

  • 孕中期解剖超声发现估计胎儿体重和/或腹围≥90百分位时,可提示临床关注后续妊娠期糖尿病及出生时巨大儿风险。
  • 在孕中期巨大儿孕妇中,发生妊娠期糖尿病或出生时巨大儿者年龄更大且更可能肥胖;产次与新生儿巨大儿相关(P=0.0003)但与妊娠期糖尿病无关(P=0.82)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To determine if large-for-gestational age (LGA) diagnosed during second-trimester ultrasound examination is associated with the development of gestational diabetes mellitus (GDM) and LGA at birth.

METHODS: This was a retrospective cohort study of all pregnant women who underwent a second-trimester anatomy ultrasound examination between 18 and 22 weeks at our institution from 2012 to 2017. Patients were included in the LGA group if estimated fetal weight and/or fetal abdominal circumference was ≥ 90th percentile for gestational age. Patients with a history of pre-GDM, multiple gestation, preterm delivery, use of betamethasone or fetal anomaly were excluded. The control group consisted of appropriate-for-gestational-age (AGA) pregnancies that were scanned at 18-22 weeks during the study period. AGA was defined as EFW > 10th percentile and ≤ 89th percentile. Prenatal and delivery records were reviewed and demographic and outcome variables were collected. Multivariable logistic regression models were applied to assess the impact of LGA diagnosed in the second trimester on the development of GDM and LGA at birth (birth weight ≥ 90th percentile).

RESULTS: The study population included 756 patients with a LGA fetus and 756 with an AGA fetus on second-trimester ultrasound examination. In patients with a LGA fetus diagnosed during the second-trimester ultrasound examination, the incidence of GDM was 6.0% and the incidence of LGA at birth was 14.9%. Among patients with a LGA fetus in the second trimester, those who developed GDM or LGA at birth were significantly older and were more likely to be obese. Moreover, parity was associated with neonatal LGA (P = 0.0003) but not with GDM (P = 0.82). On multivariable logistic regression analysis with adjustment for age, parity, change in gestational body mass index, obesity, ethnicity and neonatal sex, LGA diagnosed during the second trimester was associated significantly with GDM (adjusted odds ratio (aOR), 2.54; 95% CI, 1.29-5.03; P = 0.007) and LGA at birth (aOR, 6.85; 95% CI, 3.60-13.05; P < 0.0001).

CONCLUSIONS: LGA diagnosed during second-trimester ultrasound examination is associated with the development of GDM and LGA at birth, independent of known risk factors, and could be used to identify these women earlier for intervention. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Rekawek P, Liu L, Getrajdman C, et al. Large-for-gestational age diagnosed during second-trimester anatomy ultrasound and association with gestational diabetes and large-for-gestational age at birth. Ultrasound Obstet Gynecol. 2020. PMID: 31763722. doi:10.1002/uog.21930

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。